home > ict > winter 2020 > race for children act: product development considerations


Dear guest!
To access full content of this article, please take a minute to become a member of this site. As a registered user you will be able to view all of our vast archive's material at any time. Sign up now!

       Already registered? Please sign in.

Alternatively, please use our pay-per-view service.


News and Press Releases

Peer-reviewed translational research paves the way for first-in-class autotaxin inhibitor IOA-289 in cancer

Amsterdam, The Netherlands and Geneva, Switzerland, 16 May 2023 - iOnctura, a clinical stage biotechnology company developing breakthrough therapies for patients suffering with cancer, today announces the peer-reviewed publication of comprehensive translational research on the novel autotaxin (ATX) inhibitor IOA-289 in the ESMO journal Immuno-Oncology and Technology (IOTECH).
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement